IMMUNOBRIDGE Trademark

Trademark Overview


On Wednesday, April 3, 2024, a trademark application was filed for IMMUNOBRIDGE with the United States Patent and Trademark Office. The USPTO has given the IMMUNOBRIDGE trademark a serial number of 98482567. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, October 18, 2024. The IMMUNOBRIDGE trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:

Medical services, primarily providing and evaluating oncology rheumatology, neurology, and autoimmune disease treatment and vaccines, including neoantigen vaccines and chimeric antigen receptor (CAR) T cell therapy; healthcare services; consulting services in the field of medical care

Scientific and technological services namely, medical laboratories, scientific research and design for others in the field of pharmaceuticals, primarily for conducting and evaluating clinical trials for oncology rheumatology, neurology, and autoimmune disease treatment and vaccines, including neoantigen vaccines and chimeric antigen receptor (CAR) T cell therapy
immunobridge

General Information


Serial Number98482567
Word MarkIMMUNOBRIDGE
Filing DateWednesday, April 3, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateFriday, October 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Description of MarkThe mark consists of the wording "IMMUNOBRIDGE" in dark blue with a DNA helix inspired graphic transitioning from green to blue, against a white background.
Indication of Colors claimedThe color(s) green, teal, light blue, dark blue, and white is/are claimed as a feature of the mark.
Goods and ServicesMedical services, primarily providing and evaluating oncology rheumatology, neurology, and autoimmune disease treatment and vaccines, including neoantigen vaccines and chimeric antigen receptor (CAR) T cell therapy; healthcare services; consulting services in the field of medical care
Goods and ServicesScientific and technological services namely, medical laboratories, scientific research and design for others in the field of pharmaceuticals, primarily for conducting and evaluating clinical trials for oncology rheumatology, neurology, and autoimmune disease treatment and vaccines, including neoantigen vaccines and chimeric antigen receptor (CAR) T cell therapy

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, April 3, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, April 3, 2024
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressChicago, IL 60606

Trademark Events


Event DateEvent Description
Wednesday, April 3, 2024NEW APPLICATION ENTERED
Wednesday, April 3, 2024TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, September 4, 2024PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, September 4, 2024ASSIGNED TO LIE
Wednesday, September 11, 2024NOTICE OF DESIGN SEARCH CODE E-MAILED
Wednesday, September 11, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, October 16, 2024ASSIGNED TO EXAMINER
Friday, October 18, 2024NON-FINAL ACTION WRITTEN
Friday, October 18, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, October 18, 2024NON-FINAL ACTION E-MAILED